Company profile: Cerus
1.1 - Company Overview
Company description
- Provider of blood safety pathogen reduction systems: INTERCEPT Blood System for Platelets and Plasma (available globally with regulatory approvals); INTERCEPT Red Blood Cell System (under regulatory review in Europe and in late-stage clinical development in the US); INTERCEPT Blood System of Cryoprecipitation to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex to treat and control bleeding associated with fibrinogen deficiency.
Products and services
- INTERCEPT Blood System for Platelets and Plasma: A regulatory-approved pathogen reduction system engineered to ensure safety of platelet and plasma blood components, available globally with approvals for routine use in transfusion services
- INTERCEPT Blood System of Cryoprecipitation: An approved system that produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRCFC), used to treat and control bleeding associated with fibrinogen deficiency
- INTERCEPT Red Blood Cell System: A late-stage clinical pathogen reduction system for red blood cells, under regulatory review in Europe and in late-stage clinical development in the United States
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cerus
Ashvattha Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision nanomedicines and PET imaging agents, developing D-4517.2 for wet AMD and DME, OP-801 targeting CNS macrophages/microglia as a biomarker of neuroinflammation, OP-101 to modulate inflammatory cell activity in severe COVID-19 and other inflammatory diseases, and CSF1R Dendranib, a CSF1R tyrosine kinase inhibitor for multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ashvattha Therapeutics company profile →
Trimeris
HQ: United States
Website
- Description: Provider of HIV research and drug discovery, founded in 1993 in Morrisville, North Carolina, whose early work led to an entirely new class of anti-HIV drugs called fusion inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trimeris company profile →
PBD Biotech
HQ: United Kingdom
Website
- Description: Provider of clinical-stage phage-based diagnostics for tuberculosis, developing Actiphage TB, a blood-based test that detects Mycobacterium tuberculosis, supporting latent TB screening, active infection detection, and drug management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PBD Biotech company profile →
Vicebio
HQ: United Kingdom
Website
- Description: Provider of next-generation respiratory virus vaccines leveraging Molecular Clamp platform technology to stabilize viral glycoproteins in pre-fusion conformation, delivering broad protection and ready-to-use formulations. Pipeline includes bivalent RSV/hMPV (VXB-241), trivalent RSV-hMPV-PIV3, influenza A, SARS-CoV-2, and candidates for MERS, Ebola, and Nipah.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicebio company profile →
Calixa Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical drug development focused on a novel cephalosporin to address multi-drug resistant organisms, targeting infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calixa Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cerus
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cerus
2.2 - Growth funds investing in similar companies to Cerus
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cerus
4.2 - Public trading comparable groups for Cerus
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →